Wearable Epileptic Seizure Prediction and Alert Glasses Based on Neuromorphic Computing

NCT ID: NCT07139457

Last Updated: 2025-10-07

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 47 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-10
• Study Completion Date: 2025-12-31

Brief Summary

The NEXA study aims to evaluate a new wearable EEG device designed as smart glasses with dry electrodes positioned according to the 10-20 system. The device captures real-time brain signals to detect patterns that may predict seizures, helping people with epilepsy. This study will test the device's safety, performance, and usability before seeking regulatory approval, including FDA clearance. The NEXA device is investigational and not yet approved by the U.S. FDA. The study will involve human participants who will wear the device while data is collected and analyzed. Results will help improve the device and support future certification for medical use.

Detailed Description

The NEXA Study is a prospective observational clinical trial designed to evaluate the safety, comfort, and performance of the NEXA wearable EEG device in patients with epilepsy. NEXA uses an innovative dry electrode system (two dome-shaped electrodes at the front and two spiked electrodes above the ears) aligned with the 10-20 EEG placement system to capture high-quality brain signals without the need for gels. The device integrates real-time artifact removal algorithms and a low-power neuromorphic chip for seizure detection and prediction. The study will compare NEXA's performance against standard EEG monitoring in hospital settings across Oman, with the primary goal of determining its accuracy in seizure detection and prediction. Secondary outcomes include electrode comfort, usability, compliance, and safety. Data from this study will support regulatory submissions and demonstrate NEXA's potential as a practical and reliable solution for continuous EEG monitoring.

Conditions

Epilepsy; Epileptic Seizures; Focal Epilepsy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: SINGLE

Study Groups

Young adults

Participants aged 18-30 (equal male and female distribution) who will wear the NEXA seizure prediction glasses during both hospital-monitored and daily-life phases. Intervention involves continuous EEG monitoring, real-time seizure prediction, and alert notifications.

Group Type: EXPERIMENTAL

Wearable seizure prediction and alert glasses

Intervention Type: DEVICE

A glasses-based wearable EEG system using the international 10-20 electrode placement standard with 4 dry spiked electrodes at F7, F8, T3 and T4. The device integrates neuromorphic computing for real-time seizure prediction, an artifact removal algorithm, and multi-modal alerts (vibration, light, sound). Data is logged for model improvement. The system is intended for continuous use in both hospital-monitored and daily-life settings.

middle-aged adults

Participants aged 31-60 (equal male and female distribution) who will wear the NEXA seizure prediction glasses during both hospital-monitored and daily-life phases. Intervention involves continuous EEG monitoring, real-time seizure prediction, and alert notifications.

Group Type: EXPERIMENTAL

Wearable seizure prediction and alert glasses

Intervention Type: DEVICE

A glasses-based wearable EEG system using the international 10-20 electrode placement standard with 4 dry spiked electrodes at F7, F8, T3 and T4. The device integrates neuromorphic computing for real-time seizure prediction, an artifact removal algorithm, and multi-modal alerts (vibration, light, sound). Data is logged for model improvement. The system is intended for continuous use in both hospital-monitored and daily-life settings.

Elderly adults

Participants aged 60+ (equal male and female distribution) who will wear the NEXA seizure prediction glasses during both hospital-monitored and daily-life phases. Intervention involves continuous EEG monitoring, real-time seizure prediction, and alert notifications.

Group Type: EXPERIMENTAL

Wearable seizure prediction and alert glasses

Intervention Type: DEVICE

A glasses-based wearable EEG system using the international 10-20 electrode placement standard with 4 dry spiked electrodes at F7, F8, T3 and T4. The device integrates neuromorphic computing for real-time seizure prediction, an artifact removal algorithm, and multi-modal alerts (vibration, light, sound). Data is logged for model improvement. The system is intended for continuous use in both hospital-monitored and daily-life settings.

Interventions

Wearable seizure prediction and alert glasses

A glasses-based wearable EEG system using the international 10-20 electrode placement standard with 4 dry spiked electrodes at F7, F8, T3 and T4. The device integrates neuromorphic computing for real-time seizure prediction, an artifact removal algorithm, and multi-modal alerts (vibration, light, sound). Data is logged for model improvement. The system is intended for continuous use in both hospital-monitored and daily-life settings.

Intervention Type: DEVICE

Other Intervention Names

NEXA glasses; wearable EEG glasses; neuromorphic seizure prediction device

Eligibility Criteria

Inclusion Criteria

• Adults (≥18 years) with a confirmed epilepsy diagnosis by a neurologist or epilepsy specialist.
• History of active seizures within the last year, under stable treatment (medications, VNS, diet, or surgery) for at least 3 months.
• Capacity to provide informed consent (or via legal representative if cognitively impaired).
• Willingness to participate and sign consent.
• Residents of Oman attending Khoula Hospital or affiliated clinics.
• Stable general health without acute or severe comorbidities.
• Ability and willingness to attend study visits and follow protocols.

Exclusion Criteria

• Seizures from non-epileptic causes (e.g., psychogenic, metabolic, tumors).
• Under 18 years of age.
• Severe cognitive impairment preventing consent or protocol adherence.
• Pregnant or planning pregnancy during the study.
• Severe uncontrolled medical conditions (e.g., heart disease, cancer).
• History of non-compliance with epilepsy treatment or follow-ups.
• Severe psychiatric disorders affecting participation or safety.
• History of substance abuse interfering with study adherence.
• Known allergies or hypersensitivity to study medications or procedures.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Oman Ministry of Health

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Said Al-Mawali, PhD

Role: PRINCIPAL_INVESTIGATOR

Oman Ministry of Health

Locations

Khoula Hospital

Muscat, , Oman

Countries

Oman

Other Identifiers

Khoula Hospital

Identifier Type: OTHER

Identifier Source: secondary_id

MoH/CSR/25/29835

Identifier Type: -

Identifier Source: org_study_id